<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00954304</url>
  </required_header>
  <id_info>
    <org_study_id>HM-OXL-104</org_study_id>
    <nct_id>NCT00954304</nct_id>
  </id_info>
  <brief_title>Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet</brief_title>
  <acronym>PGP inhibitor</acronym>
  <official_title>Clinical Trial to Investigate the Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet in Healthy Male Subjects : An Open, Parallel Dose Group Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to investigate the duration of P-glycoprotein inhibition after
      oral administration of HM30181AK tablet in healthy male subject and proper dose of HM30181AK
      tablet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the duration of P-glycoprotein inhibition of HM30181AK by the Loperamide AUC measurement.</measure>
    <time_frame>Day 1~Day 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PK parameters (Cmax, AUClast, AUCinf, Tmax, T1/2, CL/F etc) of HM30181AK by measuring the blood concentration of HM30181AK</measure>
    <time_frame>Day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM30181AK 1mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM30181AK 5mg on day 4 and Loperamide 16mg(Loperamide 2mg x 8cap) on day 1,4,8,11,15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM30181AK 10mg(HM30181AK 5mg x 2tab)on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM30181AK 15mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM30181AK 60mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM30181AK 1mg</intervention_name>
    <description>HM30181AK 1mg tablet</description>
    <arm_group_label>1mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM30181AK 5mg</intervention_name>
    <description>HM30181AK 5mg tablet</description>
    <arm_group_label>5mg group</arm_group_label>
    <arm_group_label>10mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM30181AK 15mg</intervention_name>
    <description>HM30181AK 15mg tablet</description>
    <arm_group_label>15mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM30181AK 60mg</intervention_name>
    <description>HM30181AK 60mg tablet</description>
    <arm_group_label>60mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loperamide 2mg</intervention_name>
    <description>Loperamide 2mg capsule</description>
    <arm_group_label>1mg group</arm_group_label>
    <arm_group_label>5mg group</arm_group_label>
    <arm_group_label>10mg group</arm_group_label>
    <arm_group_label>15mg group</arm_group_label>
    <arm_group_label>60mg group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteers aged 20 to 50 years at screening

          2. Subjects whose weights are heavier than or equal to 50 kg and Â±20% of ideal body
             weight

               -  Ideal body weight = (height cm - 100) x 0.9

          3. Subjects who provided written, voluntary informed consent to participate in this
             clinical trial and to comply the directions including contraception after being fully
             informed of and understand this trial

        Exclusion Criteria:

          1. Subjects who have the clinically significant diseases or history in liver, kidney,
             nervous system, respiratory system, endocrine system, blood tumor and cardiovascular
             system.

          2. History of the gastrointestinal diseases which may affect the absorption of oral drugs
             (e.g., Crohn's disease) or gastrointestinal operations (excluding simple typhlotomy
             and hernia repair).

          3. The following results in laboratory test

               -  AST, ALT &gt; 1.25 x upper limits of normal

          4. Systolic blood pressure below 100 mmHg or above 150 mmHg or diastolic blood pressure
             below 65 mmHg or above 95 mmHg in vital signs

          5. History of drug allergy or other allergies which are clinically significant

          6. History of drug abuse or positive reaction for drug abuse in urine screening test

          7. Subjects who took prescription drugs or herbal medicines within 2 weeks prior to the
             first day of drug administration or OTC or vitamin preparations within 1 week prior to
             the first day of drug administration If the subjects meet other criteria, they could
             participate in the trial in the judgement of investigator.)

          8. Subjects who have participated in other clinical trial within 2 months prior to the
             first day of drug administration

          9. Whole blood donation within 2 months prior to the first day of drug administration or
             apheresis donation within 2 weeks prior to the first day of drug administration

         10. Subject who are continuously drinking alcohol (over 21 units/week) or who cannot quit
             drinking during clinical trial period

         11. Subject who are smoking over 10 cigar/day

         12. Subjects who eat food containing caffeine or grapefruit or drink alcohol in prohibited
             period

         13. Subjects who are inappropriate in the judgement of the investigator due to the reasons
             including clinical laboratory test results
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, MD., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2009</study_first_submitted>
  <study_first_submitted_qc>August 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2009</study_first_posted>
  <last_update_submitted>September 10, 2010</last_update_submitted>
  <last_update_submitted_qc>September 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kyung-mi Park/ Director</name_title>
    <organization>Hanmi Pharmaceutical Company Limited</organization>
  </responsible_party>
  <keyword>Pgp inhibitor</keyword>
  <keyword>P-glycoprotein inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Krestin</mesh_term>
    <mesh_term>Loperamide</mesh_term>
    <mesh_term>Antidiarrheals</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 15, 2015</submitted>
    <returned>June 5, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

